ANGPTL4
Basic information
Region (hg38): 19:8363289-8374370
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the ANGPTL4 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 6 | |||||
missense | 19 | 24 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 1 | 3 | 4 | |||
non coding | 1 | |||||
Total | 0 | 0 | 19 | 6 | 6 |
Variants in ANGPTL4
This is a list of pathogenic ClinVar variants found in the ANGPTL4 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
19-8364338-C-A | not specified | Uncertain significance (Apr 24, 2024) | ||
19-8364346-G-A | not specified | Uncertain significance (Oct 06, 2021) | ||
19-8364410-C-A | not specified | Uncertain significance (Dec 28, 2022) | ||
19-8364439-G-A | Plasma triglyceride level quantitative trait locus | association (May 08, 2009) | ||
19-8364441-G-A | Likely benign (May 15, 2018) | |||
19-8364507-C-T | ANGPTL4-related disorder | Benign (Mar 29, 2019) | ||
19-8364522-C-G | ANGPTL4-related disorder | Likely benign (Jul 01, 2019) | ||
19-8364532-C-T | not specified | Uncertain significance (Oct 11, 2023) | ||
19-8366033-A-G | not specified | Uncertain significance (Jan 26, 2022) | ||
19-8366196-TC-T | Benign (May 20, 2018) | |||
19-8366269-C-T | not specified | Uncertain significance (Oct 02, 2023) | ||
19-8366293-C-T | not specified | Uncertain significance (Oct 03, 2022) | ||
19-8366310-C-T | not specified | Uncertain significance (Nov 18, 2022) | ||
19-8369213-C-T | Benign (Jun 12, 2018) | |||
19-8369216-C-T | Benign (May 20, 2018) | |||
19-8369219-G-T | not specified | Uncertain significance (May 27, 2022) | ||
19-8369300-C-T | not specified | Uncertain significance (Aug 05, 2023) | ||
19-8369301-G-A | ANGPTL4-related disorder | Benign (Nov 26, 2019) | ||
19-8369320-A-T | Plasma triglyceride level quantitative trait locus | association (Jan 01, 2009) | ||
19-8371103-T-G | not specified | Uncertain significance (Oct 29, 2021) | ||
19-8371109-C-T | not specified | Uncertain significance (Feb 23, 2023) | ||
19-8371237-C-G | ANGPTL4-related disorder | Likely benign (Apr 09, 2019) | ||
19-8371297-C-T | not specified | Uncertain significance (Jun 18, 2024) | ||
19-8371298-G-A | not specified | Uncertain significance (Jan 04, 2024) | ||
19-8371316-G-A | Benign (Jun 21, 2018) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
ANGPTL4 | protein_coding | protein_coding | ENST00000301455 | 7 | 11085 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
2.31e-11 | 0.134 | 125636 | 0 | 112 | 125748 | 0.000445 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.439 | 227 | 246 | 0.921 | 0.0000151 | 2610 |
Missense in Polyphen | 98 | 99.459 | 0.98533 | 1127 | ||
Synonymous | 0.601 | 98 | 106 | 0.926 | 0.00000628 | 809 |
Loss of Function | 0.570 | 18 | 20.8 | 0.865 | 0.00000118 | 185 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000360 | 0.000359 |
Ashkenazi Jewish | 0.00120 | 0.00119 |
East Asian | 0.0000544 | 0.0000544 |
Finnish | 0.000428 | 0.000416 |
European (Non-Finnish) | 0.000640 | 0.000633 |
Middle Eastern | 0.0000544 | 0.0000544 |
South Asian | 0.000165 | 0.000163 |
Other | 0.000491 | 0.000489 |
dbNSFP
Source:
- Function
- FUNCTION: Protein with hypoxia-induced expression in endothelial cells. May act as a regulator of angiogenesis and modulate tumorigenesis. Inhibits proliferation, migration, and tubule formation of endothelial cells and reduces vascular leakage. May exert a protective function on endothelial cells through an endocrine action. It is directly involved in regulating glucose homeostasis, lipid metabolism, and insulin sensitivity. In response to hypoxia, the unprocessed form of the protein accumulates in the subendothelial extracellular matrix (ECM). The matrix-associated and immobilized unprocessed form limits the formation of actin stress fibers and focal contacts in the adhering endothelial cells and inhibits their adhesion. It also decreases motility of endothelial cells and inhibits the sprouting and tube formation (By similarity). {ECO:0000250, ECO:0000269|PubMed:12015030, ECO:0000269|PubMed:14583458}.;
- Pathway
- Cholesterol metabolism - Homo sapiens (human);PPAR signaling pathway - Homo sapiens (human);Transcriptional regulation of white adipocyte differentiation;Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha);Glucocorticoid Receptor Pathway;Nuclear Receptors Meta-Pathway;PPAR signaling pathway;Transport of small molecules;Assembly of active LPL and LIPC lipase complexes;Plasma lipoprotein assembly, remodeling, and clearance;Plasma lipoprotein remodeling
(Consensus)
Intolerance Scores
- loftool
- 0.837
- rvis_EVS
- 0.11
- rvis_percentile_EVS
- 61.91
Haploinsufficiency Scores
- pHI
- 0.0674
- hipred
- N
- hipred_score
- 0.170
- ghis
- 0.420
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.382
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Angptl4
- Phenotype
- adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); growth/size/body region phenotype; immune system phenotype; homeostasis/metabolism phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); digestive/alimentary phenotype;
Zebrafish Information Network
- Gene name
- angptl4
- Affected structure
- endothelial cell
- Phenotype tag
- abnormal
- Phenotype quality
- increased occurrence
Gene ontology
- Biological process
- angiogenesis;response to hypoxia;regulation of lipid metabolic process;cell differentiation;negative regulation of apoptotic process;positive regulation of angiogenesis;negative regulation of lipoprotein lipase activity;protein homooligomerization;triglyceride homeostasis;negative regulation of endothelial cell apoptotic process
- Cellular component
- extracellular region;extracellular space;blood microparticle
- Molecular function
- enzyme inhibitor activity;protein binding;identical protein binding